PCA treatment in nonalcoholic fatty liver disease (NAFLD) activated SIRT3 partly by suppressing fatty acid metabolism, mediated by ACSF3 [150]. This evidence concerns the gene ACSF3 and metabolic dysfunction-associated steatotic liver disease.